Development of diethylcarbamazine-loaded poly(caprolactone) nanoparticles for anti-inflammatory purpose
Preparation and characterization
DOI:
https://doi.org/10.1590/s2175-97902022e19457Keywords:
Diethylcarbamazine, Polymeric nanoparticles, Physicochemical properties, In vitro biocompatibilityAbstract
Diethylcarbamazine-loaded nanoparticles were previously evaluated for their anti-inflammatory activity. However, little is known regarding their physicochemical properties. Thus, the purpose of this study was to physiochemically characterize diethylcarbamazine-loaded poly(caprolactone) nanoparticles and evaluate their in vitro cytotoxicity. All formulations were prepared using the double-emulsion method. The average particle size was in the ranged between 298 and 364 nm and the polydispersity indexes were below 0.3. The zeta potential values were marginally negative, which may be related to drug loading, as higher loading led to an increase in the modulus of the zeta potential values. Fourier transform infrared spectroscopy (FT-IR) and X-ray powder diffraction (XRD) analysis did not reveal any chemical interactions between the chemicals used and the absence of drug in crystalline form on the nanoparticle surfaces. The in vitro drug release study revealed a concentration-dependent release from the nanoparticles into the medium. The in vitro cytotoxicity assay demonstrated the biocompatibility of the blank and loaded nanoparticles. Hence, all formulations presented good physicochemical and safety properties, corroborating the in vivo anti-inflammatory activity, previously reported by our group.
Downloads
References
Aguirre TAS, Teijeiro-Osorio D, Rosa M, Coulter IS, Alonso MJ, Brayden DJ. Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. Adv Drug Deliv Rev. 2016(Part B);106(3):223-41. doi:10.1016/j.addr.2016.02.004.
» https://doi.org/10.1016/j.addr.2016.02.004
Ali M, Afzal M, Kaushik U, Bhattacharya SM, Ahmad FJ, Dinda AK. Perceptive solutions to anti-filarial chemotherapy of lymphatic filariasis from the plethora of nanomedical sciences. J Drug Target. 2014;22(1):1-13. doi:10.3109/106118 6X.2013.832766.
» https://doi.org/10.3109/106118 6X.2013.832766
Araujo TM, Teixeira Z, Barbosa-Sampaio HC, Rezende LF, Boschero AC, Duran N, Hoehr NF. Insulin-loaded poly(epson-caprolactone) nanoparticles:efficient, sustained and safe insulin delivery system. J Biomed Nanotechnol. 2013;9(6):1098-106.
Barba AA, Dalmoro A, D’Amore M, Vascello C, Lamberti G. Biocompatible nano-micro-particles by solvent evaporation from multiple emulsions technique. J Mater Sci. 2014;49(14):5160-70. doi:10.1007/s10853-014-8224-1.
» https://doi.org/10.1007/s10853-014-8224-1
Chaves LL, Rolim LA, Gonçalves MLCM, Vieira ACC, Alves LDS, Soares MFR, et al. Study of stability and drug- excipient compatibility of diethylcarbamazine citrate. J Therm Anal Calorim. 2013;111(3):2179-86. doi:10.1007/ s10973-012-2775-7.
» https://doi.org/10.1007/ s10973-012-2775-7
Ciardelli G, Chiono V, Vozzi G, Pracella M, Ahluwalia A, Barbani N, et al. Blends of poly-(ε-caprolactone) and polysaccharides in tissue engineering applications. Biomacromolecules. 2005;6(4):1961-76. doi:10.1021/ bm0500805.
» https://doi.org/10.1021/ bm0500805
Costa A, Sarmento B, Seabra V. An evaluation of the latest in vitro tools for drug metabolism studies. Expert Opin Drug Metab Toxicol. 2014;10(1):103-19. doi:10.1517/17425255.2014 .857402.
» https://doi.org/10.1517/17425255.2014 .857402
Fathima N, Mamatha T, Qureshi HK, Anitha N, Rao JV. Drug-excipient interaction and its importance in dosage form development. J Appl Pharm Sci. 2011;1(6):66-71.
Gressl C, Brunsteiner M, Davis A, Landis M, Pencheva K, Scrivens G, et al. Drug-excipient interactions in the solid state: the role of different stress factors. Mol Pharm.2017;14(12):4560-71. doi:10.1021/acs.molpharmaceut.7b00677.
» https://doi.org/10.1021/acs.molpharmaceut.7b00677
Iqbal M, Valour JP, Fessi H, Elaissari A. Preparation of biodegradable PCL particles via double emulsion evaporation method using ultrasound technique. Colloid Polym Sci. 2015;293(3):861-73. doi:10.1007/s00396-014-3464-9.
» https://doi.org/10.1007/s00396-014-3464-9
Kamaraj N, Rajaguru PY, Issac P kumar, Sundaresan S. Fabrication, characterization, in vitro drug release and glucose uptake activity of 14-deoxy, 11, 12-didehydroandrographolide loaded polycaprolactone nanoparticles. Asian J Pharm Sci. 2017;12(4):353-62. doi:http://dx.doi.org/10.1016/j.ajps.2017.02.003
» http://dx.doi.org/10.1016/j.ajps.2017.02.003
Lafayette W, N.A. Peppas, J.J. Sahlin, Peppas NA, Sahlin JJ, N.A. Peppas, et al. A simple equation for the description of solute release. III. Coupling of diffusion and relaxation. Int J Pharm. 1989;57(2):169-72. doi:http://dx.doi.org/10.1016/0378- 5173(89)90306-2
» http://dx.doi.org/10.1016/0378- 5173(89)90306-2
Mensink MA, Frijlink HW, van der Voort Maarschalk K, Hinrichs WLJ. How sugars protect proteins in the solid state and during drying (review): Mechanisms of stabilization in relation to stress conditions. Eur J Pharm Biopharm. 2017;114:288-95. doi:10.1016/j.ejpb.2017.01.024.
» https://doi.org/10.1016/j.ejpb.2017.01.024
Peixoto CA, Silva BS. Anti-inflammatory effects of diethylcarbamazine: A review. Eur J Pharmacol. 2014;734(1):35-41. doi:10.1016/j.ejphar.2014.03.046.
» https://doi.org/10.1016/j.ejphar.2014.03.046
Rodrigues GB, Oliveira EE, Junior FJBM, Santos LAM, Oliveira WH, França MER, et al. Characterization and evaluation of nanoencapsulated diethylcarbamazine in model of acute hepatic inflammation. Int Immunopharmacol. 2017;50(May):330-7. doi:10.1016/j.intimp.2017.07.014.
» https://doi.org/10.1016/j.intimp.2017.07.014
Rodrigues GB, Oliveira EE, Junior FJBM, Santos LAM, Oliveira WH, França MER, et al. A new diethylcarbamazine formulation (NANO-DEC) as a therapeutic tool for hepatic fibrosis. Int Immunopharmacol . 2018;64(August):280-8. doi:10.1016/j.intimp.2018.09.010.
» https://doi.org/10.1016/j.intimp.2018.09.010
Rocha SWS, Silva BS, Gomes FOS, Silva AKS, Raposo C, Barbosa KPS, et al. Effect of diethylcarbamazine on chronic hepatic inflammation induced by alcohol in C57BL/6 mice. Eur J Pharmacol . 2012;689(1-3):194-203. doi:10.1016/j.ejphar.2012.05.044.
» https://doi.org/10.1016/j.ejphar.2012.05.044
Silva BS, Rodrigues GB, Rocha SWS, Ribeiro EL, Gomes FOS, Silva AKS, et al. Inhibition of NF-κB activation by diethylcarbamazine prevents alcohol-induced liver injury in C57BL/6 mice. Tissue Cell. 2014;46(5):363-71. doi:10.1016/j.tice.2014.06.008.
» https://doi.org/10.1016/j.tice.2014.06.008
Sinha VR, Bansal K, Kaushik R, Kumria R, Trehan A. Poly- ε-caprolactone microspheres and nanospheres: An overview. Int J Pharm . 2004;278(1):1-23.
Xin H, Chen L, Gu J, Ren X, wei Z, Luo J, et al. Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ε-caprolactone) nanoparticles: In vitro and in vivo evaluation. Int J Pharm . 2010;402(1-2):238-47. doi:10.1016/j.ijpharm.2010.10.005.
» https://doi.org/10.1016/j.ijpharm.2010.10.005
Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, et al. DDSolver: An add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 2010;12(3):263-71. doi:10.1208/ s12248-010-9185-1.
» https://doi.org/10.1208/ s12248-010-9185-1
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.